NCT00055185View on ClinicalTrials.gov

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

June 30, 2005

Conditions
HIV InfectionsAcquired Immune Deficiency Syndrome
Interventions
DRUG

CD4-IgG2 (PRO 542)

Trial Locations (1)

10003

Beth Israel Medical Center, New York

All Listed Sponsors
lead

Progenics Pharmaceuticals, Inc.

INDUSTRY

NCT00055185 - Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients | Biotech Hunter | Biotech Hunter